Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cidara Therapeutics, Inc. Director's Dealing 2021

Apr 5, 2021

31535_dirs_2021-04-05_825d2cc3-b811-4bed-ab38-430ddd412cf0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cidara Therapeutics, Inc. (CDTX)
CIK: 0001610618
Period of Report: 2021-01-05

Reporting Person: Oien Jessica (General Counsel & Secretary)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-01-05 Common Stock S 824 $2.06 Disposed 6141 Direct
2021-03-31 Common Stock A 2800 Acquired 8941 Direct
2021-04-01 Common Stock S 1177 $2.66 Disposed 7764 Direct

Footnotes

F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 1/1/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2: The reporting person was previously granted a performance restricted stock unit (PRSU) to vest upon the achievement of a certain milestone event that occurred on 3/31/21.

F3: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs on 03/31/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.